PRNewsWire
08 Aug 2026, 02:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA considers the analyses for Capricor's lead product candidate, Deramiocel, to be post-hoc and exploratory due to unauthorized changes to the statistical analysis plan. — Regulatory rejection of primary data analysis usually signals a high probability of BLA failure or significant delays for a lead product.
-0.90The FDA stated the benefit-risk profile for Deramiocel appeared unfavorable due to a lack of evidence supporting its effectiveness. — Direct skepticism from the FDA regarding efficacy is a primary driver for permanent valuation loss in biotech companies.
-0.80A securities class action lawsuit has been filed against Capricor Therapeutics and its executives for failing to disclose material information. — Litigation creates additional financial liability and governance risk, though it is secondary to the underlying product failure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit following an FDA briefing that questioned its data analysis and deemed the benefit-risk profile of its lead product unfavorable, causing a 64% stock price drop.
The company is mentioned as the subject of a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
